Clinical trials: Large Bowel Cancer
Chemotherapy-Induced Peripheral Neuropathy
Prevention And Treatment Of Chemotherapy-Induced Peripheral Neuropathy In Subjects With Advanced Colorectal Cancer
Prevention and treatment of the severity of symptoms of chemotherapy-induced peripheral neuropathy.
- Trial name
- NCT00380874
- Testing
- Pregabalin
- Where
- 15 sites in Australia, Germany and 4 more
- Volunteers
- 64 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Gastrointestinal Disease, Colorectal Cancer
Evaluation of the Bowel Cleansing in Hospitalized Patients Using Pure-Vu System
The aim of this study is to evaluate the potential improvement in colonoscopy procedure's outcomes when using the Pure-Vu System in hospitalized patients who are indicated for colonoscopy procedure.
- Trial name
- NCT03503162
- Testing
- Pure-Vu System
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- Motus GI Medical Technologies Ltd
Colorectal Neoplasms
Effect of Metformin on Biomarkers of Colorectal Tumor Cell Growth
The purpose of this study is to investigate the effects of short term oral Metformin therapy on biomarkers for tumor growth in subjects with newly diagnosed colon or rectal adenocarcinoma.
- Trial name
- NCT01632020
- Testing
- Metformin
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- University of Arkansas
Colorectal Cancer
An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread
This purpose of this study is to evaluate nivolumab (BMS-936558) in combination with standard of care (SOC) chemotherapy with bevacizumab for the treatment of first-line metastatic colorectal cancer (mCRC).
- Trial name
- CheckMate 9X8 (NCT03414983)
- Testing
- Nivolumab, Oxaliplatin, Leucovorin
- Where
- 49 sites in United States, Canada and 3 more
- Volunteers
- 196 people
- Sponsor
- Bristol-Myers Squibb
Colorectal Cancer
Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy
To assess the safety and efficacy of weekly (70 mg per week) and daily (10 mg per day) everolimus in patients with metastatic colorectal cancer whose cancer has progressed despite prior treatment with targeted therapy and…
- Trial name
- NCT00419159
- Testing
- Everolimus (RAD001)
- Where
- United States
- Volunteers
- 199 people
- Sponsor
- Novartis Pharmaceuticals
Colorectal Cancer
Accelerating Colorectal Cancer Screening Through Implementation Science in Appalachia
This project aims to implement a multi-level group randomized trial, delayed intervention that includes components targeting clinics, providers, patients, and the community to increase colorectal cancer (CRC) screening…
- Trial name
- ACCSIS (NCT04427527)
- Testing
- Multi-level intervention to increase CRC screening
- Where
- 2 sites in United States
- Volunteers
- 29,772 people, healthy volunteers welcome
- Sponsor
- Mark Dignan, PhD
Colorectal Cancer, Cancer of Gastrointestinal Tract
Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas
The goal of this clinical research study is to learn if abraxane can help to control colorectal and/or small bowel cancer. The safety of this drug will also be studied.
- Trial name
- NCT01730586
- Testing
- Abraxane
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Colorectal Cancer
Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer
This study will evaluate the efficacy, safety, and pharmacokinetics of Trastuzumab deruxtecan (T-DXd) in participants with human epidermal growth factor 2 (HER2)-overexpressing locally advanced, unresectable, or metastatic…
- Trial name
- DESTINY-CRC02 (NCT04744831)
- Testing
- DS-8201a 5.4 mg/kg Q3W, DS-8201a 6.4 mg/kg Q3W
- Where
- 63 sites in United States, Australia and 8 more
- Volunteers
- 122 people
- Sponsor
- Daiichi Sankyo
Metastatic Colorectal Cancer
MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC)
The research trial is testing the experimental treatment pimasertib (MSC1936369B) in combination with FOLFIRI, as second-line treatment in metastatic K Ras mutated colorectal cancer subjects.
- Trial name
- NCT01085331
- Testing
- Pimasertib, FOLFIRI
- Where
- 3 sites in Belgium, Italy and 1 more
- Volunteers
- 16 people
- Sponsor
- EMD Serono
Colorectal Cancer
U01 CRC Project for Vietnamese Americans
Colorectal cancer (CRC) is the second most commonly diagnosed cancer and the third highest cause of mortality in Vietnamese and Asian Americans.
- Trial name
- NCT03413605
- Testing
- A Multilevel CBPR Intervention
- Where
- 2 sites in United States
- Volunteers
- 801 people
- Sponsor
- Temple University
Colorectal Cancer
A Randomized Control Trial of a Simulation-based Curriculum to Enhance Skills in Colonoscopy
Colonoscopy is a commonly used medical procedure. Medical and surgical residents learning colonoscopy typically learn the procedure experientially but simulation based teaching is increasingly being integrated into training…
- Trial name
- NCT01991522
- Testing
- Curriculum Group, Self-directed learning group
- Where
- Canada
- Volunteers
- 33 people
- Sponsor
- Unity Health Toronto
Colorectal Cancer
Cetuximab & Celecoxib for Metastatic Colorectal Cancer or Colorectal Cancer That Cannot Be Removed by Surgery
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00466505
- Testing
- cetuximab, celecoxib, proteomic profiling
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Colorectal Cancer
A Study of Avastin (Bevacizumab) in Combination With mFOLFOX-6 or FOLFOXIRI in Patients With Metastatic Colorectal Cancer.
This 2 arm study will compare the resection rate of liver metastases and safety of surgery in patients with metastatic colorectal cancer and primarily unresectable liver metastases receiving treatment with Avastin in combination…
- Trial name
- NCT00778102
- Testing
- 5-FU, Irinotecan, Leucovorin
- Where
- 19 sites in Austria, France and 2 more
- Volunteers
- 80 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer
Promoting Veteran-Centered Colorectal Cancer Screening
Systematic efforts to improve colorectal cancer screening use in the VA Healthcare System have resulted in an increase in not only appropriate, but also inappropriate use of screening.
- Trial name
- PROM-IS (NCT02027545)
- Testing
- Decision Aid, Provider Education, Performance Measure Modification
- Where
- United States
- Volunteers
- 436 people
- Sponsor
- VA Office of Research and Development
Colorectal Cancer
Bevacizumab Plus Capecitabine (Xeloda) in Patients With Untreated Metastatic Colorectal Cancer
The purpose of this study is to evaluate the safety and effectiveness of the bevacizumab and capecitabine combination in frail patients with untreated metastatic colorectal cancer.
- Trial name
- NCT00203411
- Testing
- Capecitabine (Xeloda), Bevacizumab
- Where
- 12 sites in United States
- Volunteers
- 45 people
- Sponsor
- Translational Oncology Research International
Advanced or Metastatic Solid Tumors, Microsatellite Instability Low
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors
This is an open-label, non-randomized, Phase 1b/2 study to determine the safety and tolerability of NC410 when combined with a standard dose of pembrolizumab.
- Conditions
- Advanced or Metastatic Solid Tumors, Microsatellite Instability Low, Microsatellite Instability High, Microsatellite Stable
- Trial name
- NCT05572684
- Testing
- NC410, pembrolizumab
- Where
- 17 sites in United States
- Volunteers
- 97 people
- Sponsor
- NextCure, Inc.
Metastatic Colorectal Cancer
Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer
The purpose of this study is to compare the rates of Progression-Free Survival (PFS) at 12 months for patients treated with Bev-FOLFOX versus patients treated with FOLF-CB for first line treatment of metastatic colorectal cancer.
- Trial name
- NCT00252564
- Testing
- Bevacizumab, Oxaliplatin, Leucovorin
- Where
- 82 sites in United States
- Volunteers
- 247 people
- Sponsor
- US Oncology Research
Colorectal Cancer, Metastatic Cancer
Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy
The purpose of this study is to determine that panitumumab will have clinically meaningful anti-tumor activity in patients with metastatic colorectal cancer who have developed progressive disease or relapsed while on or after…
- Trial name
- NCT00083616
- Testing
- Panitumumab
- Volunteers
- 185 people
- Sponsor
- Amgen
Colorectal Cancer, Metastatic Cancer
Liver Resection and Floxuridine Plus Fluorouracil and Leucovorin in Treating Patients With Liver Metastases From Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving drugs in different ways may kill more tumor cells.
- Trial name
- NCT00002842
- Testing
- floxuridine, fluorouracil, leucovorin calcium
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- City of Hope Medical Center
Colorectal Cancer Metastatic
Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer
Combining Sorafenib with standard cytotoxic fluoropyrimidine therapy for advanced colorectal cancer may provide clinical benefit when no other treatment remains.
- Trial name
- SorCape (NCT01471353)
- Testing
- Sorafenib Plus Capecitabine (SorCape)
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of Florida